Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 1, 2021.
Article Versions
- Latest version (February 15, 2021 - 04:00).
- You are currently viewing a Latest version of this article (June 1, 2021 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2021 The Journal of Rheumatology
Author Information
- Gurjit S. Kaeley,
- Lihi Eder,
- Sibel Zehra Aydin,
- Phoebe Rich and
- Catherine J. Bakewell
- This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. 1G.S. Kaeley, MRCP, Department of Medicine, University of Florida College of Medicine, Division of Rheumatology, Jacksonville, Florida, USA; L. Eder, MD, PhD, University of Toronto, Women's College Research Institute, Toronto, Ontario, Canada; S.Z. Aydin, MD, University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada; P. Rich, MD, Oregon Dermatology & Research Center, Portland, Oregon, USA; C.J. Bakewell, MD, Salt Lake Clinic, Salt Lake City, Utah, USA.
GSK has received consultancy fees from Novartis. LE received research and educational grants or consultancy fees from AbbVie, Amgen, Pfizer, Janssen, Eli Lilly, Novartis, and Celgene. SZA has received consultancy fees from AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PR has received research funding from AbbVie, Bristol Myers Squibb, Cellceutix (now Innovation Pharmaceuticals), Eli Lilly, Kadmon Holdings, Sun Pharma/ Merck, and UCB. CJB has received consultancy fees from and/or served on speakers bureaus for AbbVie, Novartis, Pfizer, and Sanofi Genzyme/ Regeneron.
Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653–1 West 8th St, LRC 2nd Floor L-14, Jacksonville, FL 32209-6561, USA. Email: Gurjit.Kaeley@jax.ufl.edu.
Full Release Article. For details see Reprints and Permissions at jrheum.org.
Accepted for publication February 2, 2021.